Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties.

Rose Prince

2018-10-15 09:33:00 Mon ET

Several pharmaceutical companies now switch their primary focus from generic prescription drugs to medical specialties such as cardiovascular medications and radioactive therapies. The pharmaceutical giants need to focus on specific medical market niches because the Trump administration urges these firms to reduce drug prices and medical costs in America. Pfizer, Merck, and Johnson & Johnson now plan to dramatically reduce headcounts in the next few years. In addition to Pfizer, Merck, Johnson & Johnson, Novartis now plans to cut jobs through early retirement plans and layoffs worldwide. The Swiss pharmaceutical firm Novartis also plans to acquire American cancer drugmaker Endocyte for $2 billion. This strategic move accords with the broader competitive landscape that induces pharmaceutical firms to specialize in new medications and therapies that exhibit low price elasticities of patient demand. In stark contrast to generic prescription drugs, the new therapies and medications require the productive use of medical tech advances and can thus become more effective in treating specific diseases.

In a recent tweet, President Trump condemns pharmaceutical firms such as Pfizer for raising the prices of about 40 prescription drugs. In response, Pfizer CEO Ian Read decides to defer these price hikes to assuage grave concerns about patient demand and consumer protection.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Citron Research short-sellers initiate a class-action lawsuit against Tesla and its executive chairman Elon Musk.

Monica McNeil

2018-09-05 08:34:00 Wednesday ET

Citron Research short-sellers initiate a class-action lawsuit against Tesla and its executive chairman Elon Musk.

Citron Research short-sellers initiate a class-action lawsuit against Tesla and its executive chairman Elon Musk because he might have deliberately orchestr

+See More

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Peter Prince

2019-01-07 18:42:00 Monday ET

Neoliberal public choice continues to spin national taxation and several other forms of government intervention.

Neoliberal public choice continues to spin national taxation and several other forms of government intervention. The key post-crisis consensus focuses on go

+See More

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Andy Yeh Alpha

2019-02-01 15:35:00 Friday ET

Our proprietary alpha investment model outperforms most stock market indices such as S&P 500, Dow Jones, and Nasdaq.

Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implem

+See More

Warren Buffett points out that many people misunderstand his stock investment method in several ways.

Jonah Whanau

2017-06-21 05:36:00 Wednesday ET

Warren Buffett points out that many people misunderstand his stock investment method in several ways.

In his latest Berkshire Hathaway annual letter to shareholders, Warren Buffett points out that many people misunderstand his stock investment method in seve

+See More

Apple pursues an early harvest strategy that focuses on extracting healthy profits from the Mac, iPhone, and iPad.

Monica McNeil

2017-05-01 09:45:00 Monday ET

Apple pursues an early harvest strategy that focuses on extracting healthy profits from the Mac, iPhone, and iPad.

Apple now pursues an early harvest strategy that focuses on extracting healthy profits from a relatively static market for the Mac, iPhone, and iPad, all of

+See More

Internal capital markets and financial constraints

Charlene Vos

2022-10-15 09:34:00 Saturday ET

Internal capital markets and financial constraints

Internal capital markets and financial constraints Duchin (JF 2010) empirically finds that multidivisional firms with robust internal capital markets ret

+See More